The efficacy and safety of intravenous immunoglobulin infusion in 12 h for the initial treatment of Kawasaki disease

Background: Approximately 10–20 % of individuals develop a recrudescent or persistent fever after intravenous immunoglobulin (IVIG) infusion for the initial treatment of Kawasaki disease. The aim of this study was to evaluate the efficacy and safety of the initial IVIG treatment of Kawasaki disease...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Satoshi Asano, Naoya Fukushima, Kenichiro Yamada
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2024-09-01
Schriftenreihe:	Pediatrics and Neonatology
Schlagworte:	Coronary artery abnormalities Infusion duration Intravenous immunoglobulin IVIG safety Kawasaki disease
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S1875957224000032
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!